| A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ... JAMA oncology 3 (8), 1051-1058, 2017 | 752 | 2017 |
| PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project MS Tsao, KM Kerr, M Kockx, MB Beasley, AC Borczuk, J Botling, ... Journal of Thoracic Oncology 13 (9), 1302-1311, 2018 | 691 | 2018 |
| PD-L1 expression in lung cancer BTA Yu H Journal of Thoracic Oncology, 2016 | 422 | 2016 |
| Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer S Zhao, S Ren, T Jiang, B Zhu, X Li, C Zhao, Y Jia, J Shi, L Zhang, X Liu, ... Cancer immunology research 7 (4), 630-643, 2019 | 265 | 2019 |
| LAG-3 protein expression in non–small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes Y He, H Yu, L Rozeboom, CJ Rivard, K Ellison, R Dziadziuszko, K Suda, ... Journal of Thoracic Oncology 12 (5), 814-823, 2017 | 243 | 2017 |
| Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer Y He, CJ Rivard, L Rozeboom, H Yu, K Ellison, A Kowalewski, C Zhou, ... Cancer science 107 (9), 1193-1197, 2016 | 186 | 2016 |
| HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang, C Rivard, G Gao, TL Ng, ... Annals of Oncology 30 (3), 447-455, 2019 | 177 | 2019 |
| PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. journal of thoracic oncology, 2016 | 109* | 2016 |
| MHC class II expression in lung cancer Y He, L Rozeboom, CJ Rivard, K Ellison, R Dziadziuszko, H Yu, C Zhou, ... Lung Cancer 112, 75-80, 2017 | 106 | 2017 |
| Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma H Yu, Z Chen, KV Ballman, MA Watson, R Govindan, I Lanc, DG Beer, ... Journal of Thoracic Oncology 14 (1), 25-36, 2019 | 84 | 2019 |
| Early detection of lung cancer by using an autoantibody panel in Chinese population S Ren, S Zhang, T Jiang, Y He, Z Ma, H Cai, X Xu, Y Li, W Cai, J Zhou, ... Oncoimmunology 7 (2), e1384108, 2018 | 79 | 2018 |
| Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the lung-MAP S1400I phase 3 randomized clinical trial SN Gettinger, MW Redman, L Bazhenova, FR Hirsch, PC Mack, ... JAMA oncology 7 (9), 1368-1377, 2021 | 62 | 2021 |
| Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients R Zhu, HP Zhang, H Yu, H Li, YQ Ling, XQ Hu, HG Zhu Pathology-Research and Practice 204 (10), 731-742, 2008 | 62 | 2008 |
| PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes Y He, L Rozeboom, CJ Rivard, K Ellison, R Dziadziuszko, H Yu, C Zhou, ... Medical science monitor: international medical journal of experimental and …, 2017 | 61 | 2017 |
| Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution D Dora, C Rivard, H Yu, P Bunn, K Suda, S Ren, S Lueke Pickard, ... Molecular Oncology 14 (9), 1947-1965, 2020 | 60 | 2020 |
| Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation … G Xu, H Yu, X Shi, L Sun, Q Zhou, D Zheng, H Shi, N Li, X Zhang, G Shao BMC pulmonary medicine 14, 1-10, 2014 | 59 | 2014 |
| EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in … F Agustoni, K Suda, H Yu, S Ren, CJ Rivard, K Ellison, C Caldwell Jr, ... Cancer treatment reviews 72, 15-27, 2019 | 58 | 2019 |
| Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee M Mino-Kenudson, K Schalper, W Cooper, S Dacic, FR Hirsch, D Jain, ... Journal of Thoracic Oncology 17 (12), 1335-1354, 2022 | 57 | 2022 |
| The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression S Ren, Q Tian, N Amar, H Yu, CJ Rivard, C Caldwell, TL Ng, M Tu, Y Liu, ... Lung cancer 125, 115-120, 2018 | 38 | 2018 |
| CD44 facilitates epithelial-to-mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer K Suda, I Murakami, H Yu, J Kim, AC Tan, H Mizuuchi, L Rozeboom, ... Molecular cancer therapeutics 17 (10), 2257-2265, 2018 | 38 | 2018 |
